Drug Trial Radar · NCT07619118
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
May 28, 2027
Study completion May 28, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect on low-density lipoprotein-cholesterol (LDL-C) and the safety and tolerability of a fixed dose combination (FDC) of laroprovstat/rosuvastatin versus rosuvastatin alone in patients with hypercholesterolaemia with either a history of a clinical atherosclerotic cardiovascular disease (ASCVD) event or at increased risk for a first clinical ASCVD event.
Conditions
- Hypercholesterolaemia
Interventions
laroprovstat/rosuvastatin 1Combination product
daily oral dose of the laroprovstat/rosuvastatin 1
laroprovstat/rosuvastatin 2Combination product
daily oral dose of the laroprovstat/rosuvastatin 2
laroprovstat/rosuvastatin 3Combination product
daily oral dose of the laroprovstat/rosuvastatin 3
laroprovstat/rosuvastatin 4Combination product
daily oral dose of the laroprovstat/rosuvastatin 4
Placebo to match laroprovstat/rosuvastatin 1,2,3Drug
Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 1,2,3
Placebo to match laroprovstat/rosuvastatin 4Drug
Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 4
Rosuvastatin 1Drug
daily oral dose of rosuvastatin 1
Rosuvastatin 2Drug
daily oral dose of rosuvastatin 2
Rosuvastatin 3Drug
daily oral dose of rosuvastatin 3
Rosuvastatin 4Drug
daily oral dose of rosuvastatin 4
Placebo to match RosuvastatinDrug
daily oral dose of placebo to match rosuvastatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in LDL-C at 8 weeksTime frame: 8 weeks
Locations
45 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Sun City West, Arizona · Recruiting
Research Site
Gardena, California · Not yet recruiting
Research Site
Lomita, California · Not yet recruiting
Research Site
Pomona, California · Recruiting
Research Site
Sacramento, California · Not yet recruiting
Research Site
Jacksonville, Florida · Not yet recruiting
Research Site
Miami Lakes, Florida · Recruiting
Research Site
Orlando, Florida · Not yet recruiting
Research Site
Pembroke Pines, Florida · Not yet recruiting
Research Site
Conyers, Georgia · Recruiting
Research Site
Decatur, Georgia · Recruiting
Research Site
Peachtree Corners, Georgia · Not yet recruiting
Research Site
Evansville, Indiana · Not yet recruiting
Research Site
Indianapolis, Indiana · Withdrawn
Research Site
Zachary, Louisiana · Not yet recruiting
Research Site
Beltsville, Maryland · Recruiting
Research Site
Rocky Mount, North Carolina · Not yet recruiting
Research Site
Statesville, North Carolina · Not yet recruiting
Research Site
Wilmington, North Carolina · Not yet recruiting
Research Site
Fargo, North Dakota · Not yet recruiting
Research Site
Anderson, South Carolina · Not yet recruiting
Research Site
Bristol, Tennessee · Not yet recruiting
Research Site
Houston, Texas · Not yet recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Mesquite, Texas · Recruiting
Research Site
Sugar Land, Texas · Recruiting
Research Site
Burwood, Australia · Not yet recruiting
Research Site
Hope Island, Australia · Recruiting
Research Site
Hoppers Crossing, Australia · Not yet recruiting
Research Site
Woolloongabba, Australia · Recruiting
Research Site
Cambridge, Ontario, Canada · Suspended
Research Site
Guelph, Ontario, Canada · Recruiting
Research Site
Mississauga, Ontario, Canada · Recruiting
Research Site
North York, Ontario, Canada · Recruiting
Research Site
Stoney Creek, Ontario, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Berlin, Germany · Not yet recruiting
Research Site
Essen, Germany · Not yet recruiting
Research Site
Frankfurt, Germany · Not yet recruiting
Research Site
Freiburg im Breisgau, Germany · Not yet recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.